# SYROS PHARMACEUTICALS INC (SYRS)

> Institutional ownership reported to the SEC as of Q1 2025, from Form 13F filings. Source: https://holderbook.com/stocks/SYRS/

- Reporting holders: 4
- Reported value: $12.4K
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [ACADIAN ASSET MANAGEMENT LLC](https://holderbook.com/funds/916542-acadian-asset-management-llc/) | $9.0K | 329,793 | 0.0% | 5 |
| [Baader Bank Aktiengesellschaft](https://holderbook.com/funds/1542629-baader-bank-aktiengesellschaft/) | $1.9K | 83,864 | 0.0% | 2 |
| [1492 Capital Management LLC](https://holderbook.com/funds/1584087-1492-capital-management-llc/) | $1.2K | 39,244 | 0.0% | 10 |
| [XTX Topco Ltd](https://holderbook.com/funds/1828301-xtx-topco-ltd/) | $290 | 10,053 | 0.0% | 3 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q1 2025 | 4 | $12.4K |
| Q4 2024 | 47 | $1.6M |
| Q3 2024 | 69 | $44.4M |
| Q2 2024 | 70 | $105.3M |
| Q1 2024 | 77 | $112.3M |
| Q4 2023 | 60 | $147.5M |
| Q3 2023 | 49 | $49.0M |
| Q2 2023 | 54 | $34.3M |
| Q1 2023 | 57 | $28.2M |
| Q4 2022 | 54 | $39.0M |
| Q3 2022 | 48 | $62.2M |
| Q2 2022 | 61 | $34.2M |